Advertisement

Topics

Aranesp® (darbepoetin alfa) Company Profile

05:35 EDT 18th June 2018 | BioPortfolio

Aranesp® (darbepoetin alfa) is approved for the treatment of anemia associated with chronic kidney disease and chemotherapy.


News Articles [106 Associated News Articles listed on BioPortfolio]

Human medicines European public assessment report (EPAR): Aranesp, darbepoetin alfa, Revision: 39, Authorised

Japanese-developed Aranesp biosimilar shows equivalence in Phase III study

Positive results of the Phase III study for JR-131, a proposed biosimilar to darbepoetin alfa, a long-acting…

Kissei/JCR’s darbepoetin alfa biosimilar shows equivalent safety and efficacy

Japan-based collaborators Kissei Pharmaceutical (Kissei) and JCR Pharmaceuticals (JCR) announced on 17 January 2018 positive results for the phase III study of their candidate darbepoetin alfa biosimi...

A novel outpatient desensitization protocol for recombinant human erythropoietin allergy in a pediatric patient

Recombinant human erythropoietin, such as epoetin alfa and darbepoetin alfa, is an important therapy for anemia due to chronic renal failure. Allergy to recombinant human erythropoietin and the need f...

Korea’s CJ Healthcare shares biosimilar technology with China

South Korea’s CJ HealthCare, announced that it has signed a contract with China’s NCPC GeneTech Biotechnology on 31 January 2018 to export CJ-40001, a biosimilar version of darbepoetin alfa w...

FDA Approves Retacrit (epoetin alfa-epbx) as First Epoetin Alfa Biosimilar for the Treatment of Anemia

May 15, 2018 -- The U.S. Food and Drug Administration today approved Retacrit (epoetin alfa-epbx) as a biosimilar to Epogen/Procrit (epoetin alfa) for the treatment of anemia caused by chronic kidney ...

Pfizer: FDA Oks First Epoetin Alfa Biosimilar For Treatment Of Anemia

NEW YORK CITY (dpa-AFX) - Pfizer Inc. (PFE) announced the United States Food and Drug Administration approved Retacrit orepoetin alfa-epbx, a biosimilar to Epogen and Procrit (epoetin alfa), for a...

FDA Approves Pfizer’s Retacrit, the First Epoetin Alfa Biosimilar for the Treatment of Anemia

NEW YORK–(BUSINESS WIRE)–Pfizer Inc. (NYSE:PFE) today announced the United States (U.S.) Food and Drug Administration (FDA) approved RETACRIT® (epoetin alfa-epbx), a biosimilar to Epogen...

Drugs and Medications [57 Associated Drugs and Medications listed on BioPortfolio]

Ribavirin [Aurobindo Pharma Limited]

These highlights do not include all the information needed to use ribavirin safely and effectively. See full prescribing information for ribavirin tablets. Ribavirin Tablets Initial U.S. Approval: 200...

Aranesp [AMGEN INC]

These highlights do not include all the information needed to use Aranesp safely and effectively. See full prescribing information for Aranesp. Aranesp(darbepoetin alfa)injection, for intravenous or s...

Ribavirin [Sandoz Inc]

These highlights do not include all the information needed to use RIBAVIRIN TABLETS safely and effectively. See full prescribing information for RIBAVIRIN TABLETS. Ribavirin Tablets, oralInitial U.S. ...

Ribavirin [Cadila Healthcare Limited]

These highlights do not include all the information needed to use ribavirin safely and effectively. See full prescribing information for ribavirin. Initial U.S. Approval: 2002

Ribavirin [Zydus Pharmaceuticals (USA) Inc.]

These highlights do not include all the information needed to use ribavirin safely and effectively. See full prescribing information for ribavirin. Initial U.S. Approval: 2002

PubMed Articles [31 Associated PubMed Articles listed on BioPortfolio]

Change in Hemoglobin Trajectory and Darbepoetin Dose Approaching End-Stage Renal Disease: Data from the Trial to Reduce Cardiovascular Events with Aranesp Therapy Trial.

The pathogenesis of chronic kidney disease associated anemia is multifactorial and includes decreased production of erythropoietin (EPO), iron deficiency, inflammation, and EPO resistance. To better u...

A strategy to reduce inflammation and anemia treatment's related costs in dialysis patients.

This is a post-hoc analysis evaluating erythropoiesis stimulating agents' (ESA) related costs while using an additional ultrafilter (Estorclean PLUS) to produce ultrapure dialysis water located within...

Changes in in vivo confocal microscopic findings of ocular surface squamous neoplasia during treatment with topical interferon alfa-2b.

To evaluate in vivo confocal microscopy (IVCM) findings of ocular surface squamous neoplasia (OSSN) during treatment with topical interferon alfa-2b (IFN alfa-2b).

Immune tolerance induction rescue with turoctocog-alfa in a poor risk haemophilia A inhibitor young child: the history of a success.

: The development of alloantibodies against the replacement of Factor VIII (FVIII) is the major complication in haemophilia A treatment. The gold standard to eradicate inhibitors is the immune toleran...

Andexanet alfa effectively reverses edoxaban anticoagulation effects and associated bleeding in a rabbit acute hemorrhage model.

Increasing use of factor Xa (FXa) inhibitors necessitates effective reversal agents to manage bleeding. Andexanet alfa, a novel modified recombinant human FXa, rapidly reverses the anticoagulation eff...

Clinical Trials [915 Associated Clinical Trials listed on BioPortfolio]

Flexibility: A Study to Assess the Impact of Darbepoetin Alfa in Subjects withNon-Myeloid Malignancies With Anemia Due to Chemotherapy

This study will compare the efficacy (non-inferiority) of darbepoetin alfa (Aranesp®) extended dose schedule administration (EDS) versus darbepoetin alfa administered once per week (QW) i...

Effect of Darbepoetin Alfa (Aranesp®) on Anemia in Patients With Advanced Hormone Independent Prostate Cancer

The purpose of this study is to determine whether or not Aranesp® (Darbepoetin Alfa), administered every fourth week, is effective in the treatment of blood shortage (anemia) compared to ...

Evaluation of Iron Supplementation During Darbepoetin Alfa Treatment in Prophylaxis of Severe Anaemia Chemo-Induced

The purpose of this study is to evaluate the response rate obtained in an heterogeneous oncologic population treated by chemotherapy, and either by Darbepoetin alfa classic treatment or by...

A Study Comparing Two Different PROCRIT� Doses to a Dose of ARANESP� in Anemic Cancer Patients Receiving Chemotherapy

The purpose of this study is to compare hemoglobin response rates between two PROCRIT (epoetin alfa) doses and ARANESP (darbepoetin alfa) in anemic cancer patients receiving chemotherapy.

Darbepoetin Alfa (Aranesp) Following Allogeneic Stem Cell Transplantation

The purpose of this study is to find out if Darbepoetin alfa is effective in treating low red blood cell levels after allogeneic stem cell transplant. Darbepoetin alfa has been shown to h...

Companies [26 Associated Companies listed on BioPortfolio]

Aranesp® (darbepoetin alfa)

Aranesp® (darbepoetin alfa) is approved for the treatment of anemia associated with chronic kidney disease and chemotherapy.

Aranesp

Aranesp® (darbepoetin alfa) is indicated for the treatment of anemia associated with chronic renal failure (CRF), including patients on dialysis and patients not on dialysis, and for the treatment of...

Alfa Scientific Designs, Inc.

Alfa Scientific Designs, Inc. is a leader in the development and manufacture of rapid, immunoassay, point-of-care tests. As a minority, woman-owned, small business, ALFA offers a ...

Assisted Living Federation of America (ALFA)

The Assisted Living Federation of America (ALFA) is the largest national association exclusively dedicated to professionally managed assisted living communities and the seniors an...

Alfa Laval

Alfa Laval is a leading global provider of specialized products and engineered solutions. Our equipment, systems and services are dedicated to helping customers to optimize the performance of their pr...

More Information about "Aranesp® (darbepoetin alfa)" on BioPortfolio

We have published hundreds of Aranesp® (darbepoetin alfa) news stories on BioPortfolio along with dozens of Aranesp® (darbepoetin alfa) Clinical Trials and PubMed Articles about Aranesp® (darbepoetin alfa) for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Aranesp® (darbepoetin alfa) Companies in our database. You can also find out about relevant Aranesp® (darbepoetin alfa) Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Nephrology - kidney function
Nephrology is a specialty of medicine and pediatrics that concerns itself with the study of normal kidney function, kidney problems, the treatment of kidney problems and renal replacement therapy (dialysis and kidney transplantation). Systemic conditions...


Corporate Database Quicklinks



Searches Linking to this Company Record